The effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta 1 and migration-inhibitory factor levels in elderly patients with ovarian cancer
10.3760/cma.j.issn.0254-9026.2018.04.019
- VernacularTitle:腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1和巨噬细胞移动抑制因子水平的影响
- Author:
Haiyan LIU
1
;
Yan GUAN
;
Ying SUN
;
Dapeng LI
Author Information
1. 泰山医学院附属医院肿瘤科
- Keywords:
Ovarian cancer;
Transforming growth factor beta1;
Macrophage migration-inhibitory factors;
Bevacizumab;
Hyperthermia chemotherapy
- From:
Chinese Journal of Geriatrics
2018;37(4):434-436
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta1 (TGF-β1) and macrophage migration-inhibitory factor (MIF) levels in elderly patients with ovarian cancer.Methods A hundred elderly patients diagnosed with ovarian cancer from December 2011 to December 2014 at our hospital were recruited.Participants were assigned into a joint therapy group (n =50) and a thermal therapy group (n =50) according to the received treatment.Both groups were given the abdominal hyperthermia chemotherapy treatment,while the joint therapy group was additionally given Bevacizumab treatment.The effectiveness of treatment,adverse reactions,pre-and post-treatment serum TGF-β1 and MIF levels,and the 2-year survival situation in all participants were collected and analyzed.Results The therapeutic response rate and 2-year survival rate in the joint therapy group (64.0％ and 60.0％) were significantly higher than those in the thermal therapy group (44.0％ and 40.0％) (both P ＜ 0.05).There were statistically significant differences between pre-and posttreatment levels of serum TGF-β1 [(346.15 ± 35.15) ng/L vs.(201.46 ± 23.75) ng/L] and MIF [(46.32±5.16)μg/L vs.(13.48±2.45)μg/L] in the thermal therapy group,and of serum TGF-β1 [(342.26±35.01) ng/L vs.(167.52±20.26) ng/L] and MIF [(46.97±5.24)μg/L vs.(4.87±1.02)μg/L] in the joint therapy group,with greater reductions observed in the joint therapy group (P＜0.05).No significant difference in the incidence of adverse reactions was found between the two groups (P ＞ 0.05).Conclusions Abdominal Bevacizumab combined with hyperthermia chemotherapy can effectively decrease the levels of serum TGF-β1 and MIF in elderly patients with ovarian cancer and achieve improved short-term and long-term effectiveness with good safety.
